

FORM PTO-1390
 (REV. 11-2000) modified

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INVENTOR'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
 DESIGNATED/ELECTED OFFICE (DO/EO/US)
 CONCERNING A FILING UNDER 35 U.S.C. 371**

2628 USOP

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

tba **10/069180**

INTERNATIONAL APPLICATION NO.
 PCT/JP00/05523

INTERNATIONAL FILING DATE
 August 18, 2000

PRIORITY DATE CLAIMED
 August 20, 1999

TITLE OF INVENTION

Tricyclic Dihydrobenzofuran Derivative, Process for Preparing Thereof and Agent

APPLICANT(S) FOR DO/EO/US

Shigenori OHKAWA, Tadatashi HASHIMOTO, Tetsuya TSUKAMOTO

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
 Itemized Return Postcard
 Forms PCT/IB/301,304,308 and 332
 Certificate of Express Mailing

Express Mail Label No. EL 916493095 US

Date of Deposit February 15, 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.53)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

10/069

PCT/JP00/05523

2628 USOP

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO..... \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	32 - 20 =	12	x \$18.00	\$ 216.00
Independent claims	14 - 3 =	11	x \$84.00	\$ 924.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 2,030.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+	\$
SUBTOTAL =				\$ 2,030.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
TOTAL NATIONAL FEE =				\$ 2,030.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property . +				\$
TOTAL FEES ENCLOSED =				\$ 2,030.00
			Amount to be refunded:	\$
			charged:	\$

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 500799 in the amount of \$ 2,030.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 500799. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mark Chao, PhD, JD

Takeda Pharmaceuticals North America, Inc.

Suite 500, 475 Half Day Road

Lincolnshire, IL 60069 USA

(847)383-3372 fax (847)383-3481

SIGNATURE

Mark Chao, PhD, JD

NAME

37,293

REGISTRATION NUMBER

For Customer No. 23,115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	tba	Art Unit:	tba
Filed:	tba	Examiner:	tba
1 st Inventor:	S. OHKAWA	Allowed:	
For:	Tricyclic Dihydrobenzofuran Derivative, Process for Preparing Thereof and Agent	Batch:	
Atty. Dkt. No.	2628 USOP	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**USPS EXPRESS MAIL LABEL. No. EL 916493095 US****DATE IN: February 15, 2002****Itemized Papers/Items:**


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Copy of Request form of the International Application PCT/JP00/05523, (Form PCT/RO/101)(5 pages)
4. Specification - total 203 pages, including Claims 1-32 (pages 191-202), and Abstract (1 page)
5. Copy of Forms PCT/IB/301, 304, 308 and 332 (5 pages)
6. Copy of the front page of the International Application as published (WO 01/14384) (2 pages)
7. Copy of International Preliminary Examination Report (5 pages)
8. Copy of International Search Report (2 pages)
9. Assignment (2 pages) and Recordation Cover Sheet (1 page X 2)
10. Declaration and Power of Attorney (4 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX PCT
Commissioner for Patents
Washington, D.C. 20231.

on this date, 2/15/02

Dated: 2/15/02


Gail L. Winokur